8-K: Adverum Biotechnologies to Restate Prior Financial Statements Due to Accounting Errors

Adverum Biotechnologies announces it will restate financial statements from 2022-2024 due to non-cash errors related to tenant improvement allowances on a North Carolina property lease and sublease.

Summary

• Adverum Biotechnologies will restate its previously issued financial statements for the years ended December 31, 2022 and 2023, as well as the quarterly periods in 2023 and 2024.
• The restatement is due to non-cash errors in the accounting for tenant improvement allowances associated with an operating lease and sublease related to a building in North Carolina.
• The errors affect the reported amounts of non-cash assets and liabilities, and non-cash general and administrative expenses.
• The company expects to report at least one material weakness in its internal control over financial reporting following the restatement.
• Despite the accounting issues and a subtenant default, Adverum expects its cash, cash equivalents, and short-term investments to fund operations into the second half of 2025.

Sentiment

Score: 3

Explanation: The announcement of a restatement and material weakness in internal controls is a significant negative, offset slightly by the statement of sufficient cash runway.

Positives

• Adverum expects its current cash, cash equivalents, and short-term investments to fund operations into the second half of 2025.

Negatives

• Adverum is restating financial statements due to accounting errors.
• The company expects to report at least one material weakness in its internal control over financial reporting.
• A subtenant is in default under the sublease for the North Carolina premises, while Adverum remains obligated under the operating lease.

Risks

• The restatement of financial statements could negatively impact investor confidence.
• The material weakness in internal controls could lead to further scrutiny and potential regulatory issues.
• The subtenant default creates financial uncertainty for Adverum.
• Forward-looking statements regarding cash sufficiency are subject to risks and uncertainties.

Future Outlook

Adverum expects its cash, cash equivalents, and short-term investments to fund operations into the second half of 2025, but this is a forward-looking statement subject to risks and uncertainties.

Management Comments

• Management discovered non-cash errors in the Company's accounting for its operating lease and sublease of the NC Premises while preparing the consolidated financial statements as of and for the year ended December 31, 2024.
• Management is assessing the effect of these restatements on the Company's internal control over financial reporting and its disclosure controls and procedures.

Industry Context

Restatements due to accounting errors can erode investor confidence in the biotech industry, which is heavily reliant on investor funding. Companies in similar situations often face increased scrutiny from regulators and investors.

Comparison to Industry Standards

• Restatements are generally viewed negatively in the biotech industry, as they raise concerns about the accuracy of financial reporting.
• Companies like Sage Therapeutics and Biogen have faced similar scrutiny after reporting financial or operational setbacks.
• Compared to industry benchmarks, a material weakness in internal controls is a significant concern, as it suggests a higher risk of future misstatements.

Stakeholder Impact

• Shareholders may experience a decrease in stock value due to the restatement and material weakness.
• Employees may face uncertainty due to the potential impact on the company's financial stability.
• Creditors may reassess the company's creditworthiness.

Next Steps

• The Company will include the restated financial statements for the Restated Periods in its Annual Report on Form 10-K for the year ended December 31, 2024.
• Management will continue to assess the effect of these restatements on the Company's internal control over financial reporting and its disclosure controls and procedures.

Key Dates

Keywords

restatement, financial statements, accounting errors, tenant improvement allowances, material weakness, internal control, sublease default, Adverum Biotechnologies, financial reporting